Strategic Partnerships The recent partnership with the University of Texas at San Antonio presents potential collaboration opportunities for joint research projects or utilizing UTSA's resources for pharmaceutical discoveries and development.
Product Launch The launch of Cobenfy, a new medication, opens up sales prospects for pharmaceutical representatives to promote and distribute this innovative product in the market.
Award Recognition Bristol-Myers Squibb's recognition with the Financing & Liquidity Award can be leveraged in sales pitches to showcase the company's financial stability and industry leadership.
Clinical Success The FDA approval of Opdivo for resectable non-small cell lung cancer offers sales opportunities to highlight the benefits and efficacy of this treatment option to healthcare providers and patients.
Industry Expansion The $3.5bn licensing agreement for developing ex vivo T-cell therapies indicates growth in the cell and gene-therapy pipeline, signaling opportunities for sales of innovative therapies and treatments in the biotechnology sector.
731
$100M$1B
201$50M$100M
11
413$50M$100M
114$10M$50M
146$10M$50M
160$10M$50M
966$100M$1B
66
501$50M$100MMirati Therapeutics uses 8 technology products and services including Google Analytics, Oracle Business Intelligence, OpenStack, and more. Explore Mirati Therapeutics's tech stack below.
| Mirati Therapeutics Email Formats | Percentage |
| LastF@mirati.com | 88% |
| FLast@mirati.com | 5% |
| Last@mirati.com | 4% |
| First@mirati.com | 1% |
| FirstL@mirati.com | 1% |
| LastFir@mirati.com | 1% |
| First.Last@bms.com | 94% |
| LastF@bms.com | 3% |
| Last.First@bms.com | 2% |
| First.Middle@bms.com | 1% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Mirati Therapeutics, Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies that target the genetic drivers of cancer @Bristol Myers Squibb or www.bms.com
Company Overview
Media & News
Funding & FinancialsMirati Therapeutics has raised a total of $345M of funding over 8 rounds. Their latest funding round was raised on Aug 09, 2023 in the amount of $345M.
Mirati Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsMirati Therapeutics has raised a total of $345M of funding over 8 rounds. Their latest funding round was raised on Aug 09, 2023 in the amount of $345M.
Mirati Therapeutics's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com